With your own knowledge and the help of the following document:

Document 1 (Title: Pharmaceutical Technology of Modified Release Dosage Forms): Controlled release solid oral formulations represent significant pharmaceutical advances enabling optimized pharmacokinetic profiles and enhanced therapeutic outcomes through various technological approaches. Hydrophilic matrix systems utilize gel-forming polymers including hydroxypropylmethylcellulose or sodium alginate to create a viscous diffusion barrier upon hydration, with drug release regulated through manipulation of polymer type, concentration, and matrix geometry. These systems demonstrate reliable zero-order release kinetics for moderately water-soluble compounds through balanced diffusion and erosion mechanisms. Film-coated tablets incorporating insoluble polymeric membranes (e.g., ethylcellulose, polymethacrylates) provide alternative controlled-release mechanisms, with drug diffusion occurring through the intact coating following aqueous penetration. Coating thickness, polymer selection, and incorporation of pore-forming agents enable precise release rate customization for diverse therapeutic requirements. Complex multi-compartment designs including double-core formulations incorporate separate compartments with distinct release characteristics, enabling pulsatile or sequential drug delivery impossible with conventional monolithic systems. Ion-exchange resin complexation represents another effective controlled-release approach, with drug molecules ionically bound to resin particles and subsequently released through ion exchange with the gastrointestinal environment at rates determined by resin properties, drug characteristics, and local ionic conditions. Lipophilic matrix systems employing waxes, fatty acids, or glycerides create hydrophobic diffusion barriers with drug release controlled through erosion and limited aqueous penetration of the matrix. These diverse technological approaches enable pharmaceutical scientists to design continuous drug release profiles specifically tailored to therapeutic requirements, patient needs, and physicochemical properties of active pharmaceutical ingredients, collectively advancing rational drug delivery beyond conventional immediate-release formulations.
Document 2 (Title: Quantitative Analysis of Enzyme-Substrate Interactions): Enzyme kinetics represents the quantitative study of enzyme-catalyzed reactions, providing essential insights into catalytic mechanisms, metabolic regulation, and pharmacological interventions. The Michaelis-Menten model serves as the foundational framework for understanding enzyme behavior under varying substrate concentrations. This model proposes that enzymes (E) reversibly bind substrates (S) to form enzyme-substrate complexes (ES), which subsequently convert to products (P) and regenerated enzyme. Under steady-state conditions, where ES concentration remains constant, reaction velocity varies hyperbolically with substrate concentration according to the equation: v = (Vmax × [S])/(Km + [S]). Two fundamental parameters characterize this relationship: Vmax represents the maximum reaction velocity achieved at saturating substrate concentrations, while Km, the Michaelis constant, equals the substrate concentration at which reaction velocity reaches half-maximal (½Vmax). The Km value provides insight into enzyme-substrate affinity, with lower values generally indicating higher affinity. However, interpretation requires caution as Km incorporates multiple rate constants and may not directly equate to dissociation constants in complex reaction mechanisms. The ratio of these parameters (Vmax/Km) defines the catalytic efficiency, a critical metric for comparing enzymes or assessing evolutionary optimization. Experimental determination of these parameters typically employs initial velocity measurements across a range of substrate concentrations under standardized conditions of temperature, pH, and ionic strength. Linearization methods, such as Lineweaver-Burk (double-reciprocal) plots, facilitates parameter estimation, with 1/v plotted against 1/[S] yielding a straight line with slope Km/Vmax, y-intercept 1/Vmax, and x-intercept -1/Km. While historically valuable, modern computational methods using non-linear regression provide more accurate parameter estimates by avoiding statistical distortion inherent in linearization. The kinetic behavior of hexokinase, a representative enzyme catalyzing glucose phosphorylation, epitomizes these principles with relatively low Km values for glucose, reflecting its physiological role in initiating glycolysis at normal blood glucose concentrations.
Document 3 (Title: Microbiological Characteristics of Beta-Hemolytic Streptococci): Streptococcus pyogenes (Group A Streptococcus) represents a clinically significant gram-positive coccus with distinctive microbiological properties and pathophysiological mechanisms. Laboratory identification utilizes several characteristic features, with hemolytic pattern on blood agar constituting a fundamental distinction. Beta-hemolysis, characterized by complete lysis of erythrocytes creating a clear zone surrounding bacterial colonies, represents the hallmark pattern for Group A Streptococcus. This hemolytic activity derives primarily from two complementary cytolysins: streptolysin O and streptolysin S. Streptolysin O, an oxygen-labile, cholesterol-binding cytolysin, forms transmembrane pores through oligomerization, disrupting cellular integrity. This protein demonstrates antigenic properties, eliciting antibody responses (anti-streptolysin O or ASO) utilized diagnostically as evidence of recent streptococcal infection. In contrast, streptolysin S represents an oxygen-stable, non-antigenic peptide demonstrating potent membrane-damaging properties. The synergistic action of these toxins produces the characteristic zone of complete hemolysis surrounding colonies on blood agar, distinguishing beta-hemolytic streptococci from alpha-hemolytic species (producing partial hemolysis with greenish discoloration) and gamma-hemolytic variants (non-hemolytic). Beyond hemolytic properties, S. pyogenes demonstrates characteristic small colony morphology (1-2 mm diameter), susceptibility to bacitracin (differentiating it from other beta-hemolytic streptococci), positive PYR (L-pyrrolidonyl arylamidase) test, and definitively, the presence of Lancefield group A carbohydrate antigen in the cell wall. The organism's pathogenicity derives from multiple virulence factors including the antiphagocytic M protein, hyaluronic acid capsule, various adhesins, and numerous exotoxins contributing to invasive disease manifestations. Unlike certain other streptococcal species, S. pyogenes can grow aerobically, though it demonstrates enhanced growth under anaerobic or microaerophilic conditions. This facultative nature contrasts with obligate anaerobes requiring oxygen-depleted environments for viability. The organism's exotoxins contribute to both local tissue damage in pharyngeal and skin infections and systemic manifestations including scarlet fever and streptococcal toxic shock syndrome.

Answer the following list question.
Question: Among the following solid oral forms, indicate which one(s) release(s) the active ingredient continuously:
Options:
1. Hydrophilic matrix
2. Tablet with insoluble film coating
3. Double-core tablets
4. Tablets based on ion exchange resins
5. Lipophilic matrix

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ← if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.